Pacific health researchers are starting clinical trials in early 2024 to explore kava as an alternate treatment for post-traumatic stress disorder (PTSD).
Brisbane-based manufacturer and distributor Kava Korp says kava remains limited to the ‘traditional use for Islander consumers,’ and its restrictive standards are inhibiting NPD and awareness.
ASX-listed Fiji Kava says that it is preparing for ‘more firepower’ in the China market as it also explores increasing its product range across the beverage category.
This regulatory round-up will look at policy updates relating to proposed kava labelling requirements in the Oceania, the ban on celebrity endorsement of health foods in China, and South Korea’s Foods for Special Medical Purposes (FSMP) ambitions.
Changing the labelling requirements on kava would place “unreasonable and unnecessary” burden on companies, but authorities could do with post-market surveillance, Fiji Kava said in response to the ongoing regulatory debate on kava in the Oceania.
ASX-listed Fiji Kava says it is anticipating strong demand for its kava drinking powder following a lift on the import ban into country, first imposed in 2007.
ASX-listed Fiji Kava is exploring how kava could be incorporated into traditional Chinese medicine (TCM) as it seeks to expand its market presence in China, its recently appointed CEO told us.
Australia-based Fiji Kava is selling its new sleep and relax range of kava supplements for the first time globally, with domestic supermarket chain Coles being the first to stock the products.
Psychotropic plant medicine has garnered immense attention as more of such products, most notably cannabidiol (CBD) nutraceuticals, and even foods and beverages, enter the mainstream market.